Fenofibrate in the treatment of diabetic retinopathy;Fenofibrato en el tratamiento de la retinopatía diabética

Medicina Clinica

Volumn 131, Issue 1, 2008, Pages 16-17

  Simó, Rafael ^a,b,c   Hernández, Cristina ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE;

DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; HUMAN; TREATMENT OUTCOME;

EID: 45249099758     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13123045     Document Type: Editorial

References (26)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81.
2. Jones PH. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol. 2007;99:133-40.
3. Keating GM, Ormond D. Micronised fenofibrate: an update review of its clinical efficacy in the management of dyslpidaemia. Drugs. 2002;62:1909-44.
4. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849-61.
5. Keech A, Mitchell P, Summanen P, O'Day, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370:1687-97.
6. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995;38:437-44.
7. Congdom N, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290:2057-60.
8. Hernández C, Giralt J, Simó R. Tratamiento de la retinopatía diabética. Endocrinol Nutr. 2008;55 Supl 2:92-8.
9. Hernández C, Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs. 2007;16:1209-26.
10. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C b inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188-97.
11. PKC-DRS2 Group; Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-30.
12. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008. [Epub ahead of print]
13. Zhang J, McGwin G. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol. 2007;125:1096-9.
14. Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Dyslipidaemia and microvascular disease in the retina. Eye. 2005;19:861-8.
15. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;53:2883-92.
16. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1-11.
17. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunt in the management of diabetic macular edema. Am J Ophthalmology. 2004;137:675-82.
18. Chew EY, Ambrosious WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. Rationale design and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE). Am J Cardiol. 2007; 99 Suppl 12A:103-11.
19. Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodríguez IR. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis. 2006;12:1319-33.
20. García-Ramírez M, Canals F, Hernández C, Colomé N, Ferrer C, Carrasco E, et al. Proteomic analysis of human vitreous fluid by fluorescencebased difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia. 2007;50:1294-303.
21. Simó R, Higuera M, García-Ramírez M, Canals F, García Arumí J, Hernández C. Apo A1 and apo H are elevated in the vitreous fluid and overexpressed in the retina from diabetic patients. Arch Ophthalmol. En prensa 2008.
22. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand F, Opolon P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci. 2003;60:810-9.
23. Meissner M, Stein C, Urbich C, Reisinger K, Suske G, Staels B, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Cir Res. 2004;94:324-32.
24. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademarker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglycemia and the metabolic syndrome. Diabetes Care. 2007;17:31-55.
25. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role of inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-2.
26. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemotactic protein-1 and interleukin-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:79-22.